0849 GMT - Roche is well positioned for growth in the medium-term on expedited obesity-drug ambitions, Baader Helvea analyst Abhishek Raval says in a note. The Swiss pharmaceutical company recently acquired a mid-stage weight-loss drug candidate from Danish biotech Zealand Pharma. The company also has a diversified portfolio of disease areas, Raval notes. "With significant manufacturing and commercial might...the Swiss giant could become a serious contender in the obesity market," he says. Historically, Roche has usually been the market-leader in many of the disease areas it targets, the analyst says. Any progress in Roche's obesity pipeline could fuel the already solid share-price performance in recent months, he adds. Shares fall 0.9% to 302.90 Swiss francs. (helena.smolak@wsj.com)
(END) Dow Jones Newswires
March 26, 2025 04:49 ET (08:49 GMT)
Copyright (c) 2025 Dow Jones & Company, Inc.
免责声明：投资有风险，本文并非投资建议，以上内容不应被视为任何金融产品的购买或出售要约、建议或邀请，作者或其他用户的任何相关讨论、评论或帖子也不应被视为此类内容。本文仅供一般参考，不考虑您的个人投资目标、财务状况或需求。TTM对信息的准确性和完整性不承担任何责任或保证，投资者应自行研究并在投资前寻求专业建议。